Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
eVOLVE-Lung02: Volrustomig plus chemotherapy versus pembrolizumab plus chemotherapy as first-line treatment for metastatic non-small cell lung cancer
CTR20250188Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Apr 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of volrustomig in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Apr 2025; status: active.
02
Drugs
volrustomig
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20250188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250188.